Reportlinker Adds Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis

NEW YORK, Oct. 12 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis

http://www.reportlinker.com/p0312075/Musculoskeletal-Disorders-Therapeutics-to-2016---Introduction-of-Monoclonal-Antibodies-with-First---in---class-Mechanism-of-Action-to-Increase-Treatment-Options-in-Osteoporosis-and-Rheumatoid-Arthritis.html

Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis

Summary

GBI Research's report, "Musculoskeletal Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First-in-class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis", provides in-depth analysis of unmet needs, drivers and barriers that impact the global musculoskeletal disorders market. The report analyzes the markets for musculoskeletal disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The Scope of this report includes:

- Annualized market data for the musculoskeletal disorders therapeutics market from 2001 to 2009, with forecasts to 2016.

- Data and analysis on the musculoskeletal disorders therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Market Data on geographical landscape and therapeutic landscape including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- Key drivers and restraints that have created significant impact on the market.

- Competitive landscape of the global musculoskeletal disorders therapeutics market including top companies benchmarking. The key companies studied in this report are Roche/Genentech, Novartis, Amgen, Merck/Schering-Plough, Pfizer/Wyeth, Bristol-Myers Squibb and Eli Lilly, Procter and Gamble, Johnson and Johnson, Abbott Laboratories and Boehringer Ingelheim

- Key M&A activities, Licensing Agreements, that have taken place between 2008 and 2009 in the musculoskeletal disorders therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to :

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 8

2 Global Musculoskeletal Disorders Therapeutics Market: Introduction 11

2.1 GBI Research Report Guidance 12

3 Global Musculoskeletal Disorders Therapeutics Market: Market Overview 13

3.1 Introduction 13

3.2 Revenue Forecasts for the Global Musculoskeletal Disorders Therapeutics Market 14

3.2.1 Revenue 14

3.2.2 Annual Cost of Treatment (ACT) 15

3.2.3 Treatment Usage Patterns 16

3.3 Generics in Musculoskeletal Disorders Therapeutics Market 21

4 Global Musculoskeletal Disorders Therapeutics Market: Geographical Landscape 22

4.1 Revenue Analysis By Geography 22

4.2 The US 24

4.2.1 Revenue 24

4.2.2 Annual Cost of Treatment 26

4.2.3 Treatment Usage Patterns 28

4.3 Top Five EU Countries 34

4.3.1 Revenue 34

4.3.2 Annual Cost of Treatment 36

4.3.3 Treatment Usage Patterns 38

4.4 Japan 44

4.4.1 Revenue 44

4.4.2 Annual Cost of Treatment 46

4.4.3 Treatment Usage Patterns 47

5 Global Musculoskeletal Disorders Therapeutics Market: Therapeutic Landscape 53

5.1 Osteoporosis Therapeutics Market 53

5.1.1 Introduction 53

5.1.2 Revenue 53

5.1.3 Annual Cost of Treatment 55

5.1.4 Treatment Usage Patterns 57

5.1.5 Drivers and Barriers for the Osteoporosis Therapeutics Market 64

5.1.6 Opportunity and Unmet Need 65

5.2 Osteoarthritis Therapeutics Market 66

5.2.1 Introduction 66

5.2.2 Revenue 66

5.2.3 Annual Cost of Treatment 68

5.2.4 Treatment Usage Patterns 69

5.2.5 Drivers and Barriers for the Osteoarthritis Therapeutics Market 76

5.2.6 Opportunity and Unmet Need 77

5.3 Rheumatoid Arthritis Therapeutics Market 78

5.3.1 Introduction 78

5.3.2 Revenue 78

5.3.3 Annual Cost of Treatment 80

5.3.4 Treatment Usage Patterns 82

5.3.5 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 88

5.3.6 Unmet Need for Rheumatoid Arthritis Therapeutics Market 89

5.4 Muscular Dystrophy Therapeutics Market 90

5.4.1 Introduction 90

5.4.2 Revenue 90

5.4.3 Annual Cost of Treatment 92

5.4.4 Treatment Usage Patterns 93

5.4.5 Drivers and Barriers for the Muscular Dystrophy Therapeutics Market 100

5.4.6 Unmet Need for Muscular Dystrophy Therapeutics Market 101

6 Global Musculoskeletal Disorders Therapeutics Market: Pipeline Analysis 102

6.1 Introduction 102

6.1.1 Research and Development Pipeline – Osteoarthritis 103

6.1.2 Research and Development Pipeline – Osteoporosis 109

6.1.3 Research and Development Pipeline – Rheumatoid Arthritis 118

6.1.4 Research and Development Pipeline – Muscular Dystrophy 129

6.2 Profiles of Promising Drugs in the Musculoskeletal Disorders Therapeutics Market 132

6.2.1 Catena/Sovrima (Idebenone) 132

6.2.2 IPlex(TM) (Mecasermin Rinfabate) 132

6.2.3 CG5503 (Tapentadol ER) 133

7 Global Musculoskeletal Disorders Therapeutics Market: Competitive Landscape 134

7.1 Evolving competitive landscape 134

7.1.1 Major Players 135

7.2 Market Share Analysis 136

7.3 Competitive Profiling 137

7.3.1 Novartis AG 137

7.3.2 Pfizer 138

7.3.3 Hoffmann-La Roche Ltd. 139

7.3.4 Merck & Co., Inc 141

7.3.5 Eli Lilly and Company 143

7.3.6 Abbott Laboratories 145

7.3.7 Johnson & Johnson 146

7.3.8 Amgen Inc. 147

7.3.9 Procter & Gamble Company 149

7.3.10 Bristol-Myers Squibb Company 150

8 Global Musculoskeletal Disorders Therapeutics Market: M&A Landscape 152

8.1 Overview 152

8.1.1 Pfizer Acquires Wyeth 153

8.1.2 Cephalon Acquires Arana Therapeutics 153

8.1.3 Aspen Pharmacare Acquires Sigma Pharmaceuticals 153

8.2 R&D Licensing Agreements 153

8.2.1 Deals by Phase 153

8.2.2 Deals by Geography 154

8.2.3 Deals by Value ($) 155

8.2.4 Preclinical 156

8.2.5 Phase I 157

8.2.6 Phase II 158

8.2.7 Phase III 159

8.2.8 Approved 160

8.2.9 Marketed Drugs 162

9 Global Musculoskeletal Disorders Therapeutics Market: Appendix 163

9.1 Market Definitions 163

9.2 Abbreviations 163

9.3 Research Methodology 165

9.3.1 Coverage 165

9.3.2 Secondary Research 165

9.3.3 Primary Research 166

9.3.4 Forecasts 166

9.3.5 Expert Panel Validation 169

9.4 Contact Us 169

9.5 Disclaimer 169

9.6 Sources 169

1.1 List of Tables

Table 1: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2001-2009 14

Table 2: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016 14

Table 3: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 15

Table 4: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 15

Table 5: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2001-2009 16

Table 6: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2009-2016 17

Table 7: Musculoskeletal Disorders Therapeutics Market, Global, Generics Sales Forecast ($bn), 2009-2016 21

Table 8: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2001-2009 22

Table 9: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2009-2016 23

Table 10: Musculoskeletal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2001-2009 25

Table 11: Musculoskeletal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2009-2016 25

Table 12: Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2001-2009 27

Table 13: Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2009-2016 27

Table 14: Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2001-2009 28

Table 15: Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2009-2016 29

Table 16: Musculoskeletal Disorders Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2001-2009 35

Table 17: Musculoskeletal Disorders Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2009-2016 35

Table 18: Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2001-2009 37

Table 19: Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2009-2016 37

Table 20: Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU, Treatment Usage Patterns (Millions), 2001-2009 38

Table 21: Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU, Treatment Usage Patterns(Millions), 2009-2016 39

Table 22: Musculoskeletal Disorders Therapeutics Market, Japan, Revenue ($bn), 2001-2009 45

Table 23: Musculoskeletal Disorders Therapeutics Market, Japan, Revenue ($bn), 2009-2016 45

Table 24: Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2001-2009 46

Table 25: Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2009-2016 46

Table 26: Musculoskeletal Disorders Therapeutics Market , Japan, Treatment Usage Patterns (Millions), 2001-2009 47

Table 27: Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Usage Patterns (Millions), 2009-2016 48

Table 28: Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2001-2009 54

Table 29: Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2009-2016 54

Table 30: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 56

Table 31: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 56

Table 32: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2001-2009 58

Table 33: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2009-2016 59

Table 34: Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2001-2009 67

Table 35: Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2009-2016 67

Table 36: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 68

Table 37: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 68

Table 38: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2001-2009 70

Table 39: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2009-2016 71

Table 40: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2001-2009 79

Table 41: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2009-2016 79

Table 42: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 81

Table 43: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 81

Table 44: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns, 2001-2009 83

Table 45: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns, 2009-20016 83

Table 46: Muscular Dystrophy Therapeutics Market, Global, Revenue ($m), 2001-2009 91

Table 47: Muscular Dystrophy Therapeutics Market, Global, Revenue ($m), 2009-2016 91

Table 48: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 92

Table 49: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 92

Table 50: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000's), 2001-2009 94

Table 51: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000's), 2009-2016 95

Table 52: Musculoskeletal Disorders Therapeutics- Osteoarthritis Pipeline, Discovery Stage Molecules, 2010 104

Table 53: Musculoskeletal Disorders Therapeutics- Osteoarthritis Pipeline, Preclinical Molecules, 2010 105

Table 54: Musculoskeletal Disorders Therapeutics- Osteoarthritis Pipeline, Phase I Molecules, 2010 106

Table 55: Musculoskeletal Disorders Therapeutics- Osteoarthritis Pipeline, Phase II Molecules, 2010 107

Table 56: Musculoskeletal Disorders Therapeutics- Osteoarthritis Pipeline, Phase III Molecules, 2010 108

Table 57: Musculoskeletal Disorders Therapeutics- Osteoarthritis Pipeline, NDA Filed Molecules, 2010 109

Table 58: Musculoskeletal Disorders Therapeutics- Osteoporosis Pipeline, Discovery Stage Molecules, 2010 110

Table 59: Musculoskeletal Disorders Therapeutics- Osteoporosis Pipeline, Preclinical Molecules, 2010 110

Table 60: Musculoskeletal Disorders Therapeutics- Osteoporosis Pipeline, Phase I Molecules, 2010 111

Table 61: Musculoskeletal Disorders Therapeutics- Osteoporosis Pipeline, Phase II Molecules, 2010 112

Table 62: Musculoskeletal Disorders Therapeutics- Osteoporosis Pipeline, Phase III Molecules, 2010 115

Table 63: Musculoskeletal Disorders Therapeutics- Rheumatoid Arthritis Pipeline, Discovery Stage Molecules, 2010 119

Table 64: Musculoskeletal Disorders Therapeutics- Rheumatoid Arthritis Pipeline, Preclinical Molecules, 2010 120

Table 65: Musculoskeletal Disorders Therapeutics- Rheumatoid Arthritis Pipeline, Phase I Molecules, 2010 123

Table 66: Musculoskeletal Disorders Therapeutics- Rheumatoid Arthritis Pipeline, Phase II Molecules, 2010 125

Table 67: Musculoskeletal Disorders Therapeutics- Rheumatoid Arthritis Pipeline, Phase III Molecules, 2010 128

Table 68: Musculoskeletal Disorders Therapeutics- Rheumatoid Arthritis Pipeline, NDA Filed Molecules, 2010 129

Table 69: Musculoskeletal Disorders Therapeutics- Muscular Dystrophy Pipeline, Discovery Stage Molecules, 2010 129

Table 70: Musculoskeletal Disorders Therapeutics- Muscular Dystrophy Pipeline, Preclinical Molecules, 2010 130

Table 71: Musculoskeletal Disorders Therapeutics- Muscular Dystrophy Pipeline, Phase I Molecules, 2010 130

Table 72: Musculoskeletal Disorders Therapeutics- Muscular Dystrophy Pipeline, Phase II Molecules, 2010 131

Table 73: Musculoskeletal Disorders Therapeutics- Muscular Dystrophy Pipeline, Phase III Molecules, 2010 131

Table 74: Musculoskeletal Disorders Therapeutics Market, Global, Major M&A Deals, 2008-2010 152

Table 75: Musculoskeletal Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008-2010 156

Table 76: Musculoskeletal Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase I, 2008-2010 157

Table 77: Musculoskeletal Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II, 2008-2010 158

Table 78: Musculoskeletal Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III, 2008-2010 159

Table 79: Musculoskeletal Disorders Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008-2010 160

Table 80: Musculoskeletal Disorders Therapeutics Market, Global, Licensing Agreements for Marketed Drugs, 2008-2010 162

1.2 List of Figures

Figure 1: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2001-2016 14

Figure 2: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 15

Figure 3: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns, 2001-2016 16

Figure 4: Musculoskeletal Disorders Therapeutics Market, Global, Diseased Population (Millions), 2001-2016 17

Figure 5: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Seeking Population (Millions), 2001-2016 18

Figure 6: Musculoskeletal Disorders Therapeutics Market, Global, Diagnosis Population (Millions), 2001-2016 19

Figure 7: Musculoskeletal Disorders Therapeutics Market, Global, Prescription Population (Millions), 2001-2016 20

Figure 8: Musculoskeletal Disorders Therapeutics Market, Global, Generics Sales Forecast ($bn), 2009-2016 21

Figure 9: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2001-2016 22

Figure 10: Musculoskeletal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2001-2016 24

Figure 11: Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of treatment ($), 2001-2016 26

Figure 12: Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2001-2016 28

Figure 13: Musculoskeletal Disorders Therapeutics Market, the US, Diseased Population (Millions), 2001-2016 30

Figure 14: Musculoskeletal Disorders Therapeutics Market, the US, Treatment Seeking Population (Millions), 2001-2016 31

Figure 15: Musculoskeletal Disorders Therapeutics Market, The US, Diagnosis Population (Millions), 2001-2016 32

Figure 16: Musculoskeletal Therapeutics Market, The US, Prescription Population (Millions), 2001-2016 33

Figure 17: Musculoskeletal Disorders Therapeutics Market , Top Five EU Countries, Revenue Forecasts ($bn), 2001-2016 34

Figure 18: Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2001-2016 36

Figure 19: Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU, Treatment Usage Patterns (Millions), 2001-2016 38

Figure 20: Musculoskeletal Disorders Therapeutics Market , Top Five Countries in the EU , Diseased Population (Millions), 2001-2016 40

Figure 21: Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU , Treatment Seeking Population (Millions), 2001-2016 41

Figure 22: Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU , Diagnosis Population (Millions), 2001-2016 42

Figure 23: Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU , Prescription Population (Millions), 2001-2016 43

Figure 24: Musculoskeletal Disorders Therapeutics Market, Japan, Revenue ($bn), 2001-2016 44

Figure 25: Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2001-2016 46

Figure 26: Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Usage Patterns (Millions), 2001-2016 47

Figure 27: Musculoskeletal Disorders Therapeutics Market, Japan, Diseased Population (Millions), 2001-2016 49

Figure 28: Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Seeking Population (Millions), 2001-2016 50

Figure 29: Musculoskeletal Disorders Therapeutics Market, Japan, Diagnosis Population (Millions), 2001-2016 51

Figure 30: Musculoskeletal Disorders Therapeutics Market, Japan, Prescription Population (Millions), 2001-2016 52

Figure 31: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2001-2016 53

Figure 32: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 55

Figure 33: Osteoporosis Therapeutics Market, Global, Drivers and Restraints, 2009 57

Figure 34: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2001-2016 58

Figure 35: Osteoporosis Therapeutics Market, Global, Diseased Population (Millions), 2001-2016 60

Figure 36: Osteoporosis Therapeutics Market, Global, Treatment Seeking Population (Millions), 2001-2016 61

Figure 37: Osteoporosis Therapeutics Market, Global, Diagnosis Population (Millions), 2001-2016 62

Figure 38: Osteoporosis Therapeutics Market , Global, Prescription Population (Millions), 2001-2016 63

Figure 39: Osteoporosis Therapeutics Market , Global, Market Drivers and Barriers, 2009 64

Figure 40: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2001-2016 66

Figure 41: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 68

Figure 42: Osteoarthritis Therapeutics Market, Global, Drivers and Restraints, 2009 69

Figure 43: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2001-2016 70

Figure 44: Osteoarthritis Therapeutics Market, Global, Diseased Population (Millions), 2001-2016 72

Figure 45: Osteoarthritis Therapeutics Market, Global, Treatment Seeking Population (Millions), 2001-2016 73

Figure 46: Osteoarthritis Therapeutics Market, Global, Diagnosis Population (Millions), 2001-2016 74

Figure 47: Osteoarthritis Therapeutics Market, Global, Prescription Population (Millions), 2001-2016 75

Figure 48: Osteoarthritis Therapeutics Market , Global, Market Drivers and Barriers, 2009 76

Figure 49: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2001-2016 78

Figure 50: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 80

Figure 51: Rheumatoid Arthritis Therapeutics Market, Global, Drivers and Restraints, 2009 82

Figure 52: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (000's), 2001-2016 83

Figure 53: Rheumatoid Arthritis Therapeutics Market, Global, Diseased Population (Millions), 2001-2016 84

Figure 54: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Seeking Population (Millions), 2001-2016 85

Figure 55: Rheumatoid Arthritis Therapeutics Market, Global, Diagnosis Population (Millions), 2001-2016 86

Figure 56: Rheumatoid Arthritis Therapeutics Market, Global, Prescription Population (000's), 2001-2016 87

Figure 57: Rheumatoid Arthritis, Market Drivers and Barriers, 2009 88

Figure 58: Muscular Dystrophy Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016 90

Figure 59: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 92

Figure 60: Muscular Dystrophy Therapeutics Market, Global, Drivers and Restraints, 2009 93

Figure 61: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000's), 2001-2016 94

Figure 62: Muscular Dystrophy Therapeutics Market, Global, Diseased Population (000's), 2001-2016 96

Figure 63: Muscular Dystrophy Therapeutics Market, Global, Treatment Seeking Population (000's), 2001-2016 97

Figure 64: Muscular Dystrophy Therapeutics Market, Global, Diagnosis Population (000's), 2001-2016 98

Figure 65: Muscular Dystrophy Therapeutics Market, Global, Prescription Population (000's), 2001-2016 99

Figure 66: Muscular Dystrophy, Drivers and Barriers, 2009 100

Figure 67: Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline by Indication (%), 2010 102

Figure 68: Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 103

Figure 69: Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline by Phase in Osteoarthritis Therapeutics Market (%), 2010 103

Figure 70: Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline by Phase in Osteoporosis Therapeutics Market (%), 2010 109

Figure 71: Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline by Phase in Rheumatoid Arthritis Therapeutics Market (%), 2010 118

Figure 72: Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline by Phase in Muscular Dystrophy Therapeutics Market (%), 2010 129

Figure 73: Musculoskeletal Disorders Therapeutics Market, Global, Competitive Landscape, 2009 134

Figure 74: Musculoskeletal Disorders Therapeutics Market, Global, Top 10 Companies Sales ($bn), 2009 135

Figure 75: Musculoskeletal Disorders Therapeutics Market, Global, Market Share Analysis, 2009 136

Figure 76: Musculoskeletal Disorders Therapeutics Market, Global, Top three Companies Benchmarking, 2009 137

Figure 77: Musculoskeletal Disorders Therapeutics Market, Global, Major Licensing Agreements By Each Phase, 2008-2010 153

Figure 78: Musculoskeletal Disorders Therapeutics Market, Global, Major Licensing Agreements By Geography, 2008-2010 154

Figure 79: Musculoskeletal Disorders Therapeutics Market, Global, Major Licensing Agreements By Value, 2008-2010 155

Figure 80: GBI Research Market Forecasting Model 168

Companies mentioned

Novartis AG

Pfizer

Hoffmann-La Roche Ltd.

Merck & Co., Inc

Eli Lilly and Company

Abbott Laboratories

Johnson & Johnson

Amgen Inc.

Procter & Gamble Company

Bristol-Myers Squibb Company

To order this report:

Biological Therapy Industry: Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis

Biological Therapy Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker